News
Caris Life Sciences spikes by over 30% in IPO debut, embraces AI as future of oncology In an interview, the company’s president said cancer doctors need not be afraid of machine learning.
The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion.
Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering ...
Carlsmed Inc. launched its IPO at a price of $14 to $16 per share for 6.7 million shares, which would raise just over $100.5 ...
IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the ...
Caris Life Sciences, Inc. (CAI) is planning to raise $400 million in an initial public offering on Wednesday, June 18th, IPO Scoop reports. The company will be issuing 23,500,000 shares at $16.00 ...
Heartflow's quarterly loss widened over the year-ago period, the healthcare company disclosed in its paperwork for a U.S. initial public offering on Thursday, at a time when it looks to tap into ...
Today’s IPO for Caris Life Sciences (CAI) is indicated to open at $30 after pricing at $21. the company priced 23,529,412 shares in the IPO BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC are ...
IRVING, Texas, June 9, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results